Abstract: Provided herein are methods for determining levels of cell lysis in samples, particularly sampled in which amounts of non-self cell-free DNA may be determined.

Abstract: Provided herein are materials and methods relating to cell-free DNA. In particular, the technology relates to methods and materials for the preparation and handling of blood samples for future use in applications involving cell-free DNA.

Abstract: This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.

Abstract: This invention relates to methods and compositions for assessing risk based on amount(s) of total cell-free DNA in a subject, such as including at least one pre-operative sample from the subject.

Abstract: This invention relates to compositions and methods for treating subjects in need of mechanical support, such as those who have had surgery and/or are in need of pro-inflammatory reduction. The mechanical support can comprise a filter that reduces the amount of cell-free DNA in the subject, in some embodiments. The subject may be treated with cf-DNA inhibitors in other embodiments.

Abstract: This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.

Abstract: This invention relates to methods and compositions for assessing or monitoring an amount of donor-specific fraction cell-free DNA from a transplant subject and comparing to specific threshold values for making treatment management decisions.

Abstract: This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.

Abstract: Provided herein are materials and methods relating to cell-free DNA. In particular, the technology relates to methods and materials for the preparation and handling of blood samples for future use in applications involving cell-free DNA.

Abstract: This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.

Abstract: This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a subject having a pro-inflammatory response, such as a pro-inflammatory response associated with an infection, such as a COVID-19 infection. This invention also relates to compositions and methods for treating subjects having or suspected of having a pro-inflammatory response, such as a pro-inflammatory response associated with an infection, such as a COVID-19 infection. In embodiments, there is a risk of an inappropriate or detrimental pro-inflammatory response, such as in a subject with a COVID-19 infection. The methods and composition provided herein can be used to determine severity and risk of complications in a subject. The methods and composition provided herein can also be used to assess the effectiveness of a therapy in a subject, such as a COVID-19 subject.

Abstract: This invention relates to methods and compositions for assessing an amount of donor-specific fraction of cell-free DNA, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant organ injury (e.g., cellular injury), cellular rejection grade, antibody-mediated rejection, cardiac allograft vasculopathy, and/or cardiac arrest in a transplant subject.

Abstract: This invention relates to methods and compositions for assessing risk by obtaining the product of a donor-specific fraction and total cell-free DNA, such as from a transplant subject. The methods and compositions provided herein can be used to assess a transplant subject to determine risk of one or more transplant complications (e.g., death) and/or a need for monitoring or treatment.

Abstract: This invention relates to methods and compositions for assessing amount(s) of total cell-free DNA in a subject. Such amount(s) can be used to determine risk in a subject, which subjects are non-transplant subjects, such as surgical subjects, in some preferred embodiments.

Abstract: This invention relates to methods and compositions for assessing an amount of non-native nucleic acids in a sample, such as from a subject, and/or noise, background or discordance quality check (QC). The methods and compositions provided herein can be used to determine risk of a condition, such as cancer, in a subject.

Abstract: This invention relates to methods and compositions for assessing the suitability of a graft for transplantation or implantation by measuring total and/or specific cell-free nucleic acids (such as cf-DNA) and/or cell lysis. Specifically, the method comprising obtaining an amount of total cf DNA and/or graft-specific cfDNA released from a potential graft (e.g., ex vivo), e.g., prior to contacting of the potential graft with blood cells of a potential recipient, and/or subsequent to contacting of the potential graft or cells thereof with blood cells from a potential recipient, assessing the amount(s) to determine the suitability of the potential graft for transplantation or implantation.

Abstract: This invention relates to methods and compositions for assessing an amount of total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to determine risk of complications following transplantation, including infection, cardiac arrest, and death, in a subject.

Abstract: This invention relates to methods and compositions for monitoring an amount of donor-specific fraction and/or total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to assess a transplant subject to determine whether the subject has a “normal” or desirable decrease in cell-free DNA over the first few days following a transplant. Deviations from the “normal” course may be indicative of one or more transplant complications and/or a need for additional monitoring or treatment.

Abstract: This invention relates to methods and compositions for assessing an amount of donor-specific fraction of cell-free DNA, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant organ injury (e.g., cellular injury), cellular rejection grade, antibody-mediated rejection, cardiac allograft vasculopathy, and/or cardiac arrest in a transplant subject.

Abstract: This invention relates to methods and systems for assessing an amount of non-subject nucleic acids, such as donor-specific cell-free DNA, in a sample from a subject. The methods and systems can include the simulation of non-subject genotype when unknown. The methods and systems provided herein can be used to determine risk of a condition, such as transplant rejection.